Clinical evaluation of preoperative abdominal aortic balloon occlusion in patients with placenta increta or percreta
Abstract Background Placenta increta or percreta will result in severe postpartum hemorrhage and become a research hotspot in obstetrics. Preoperative abdominal aortic balloon occlusion (AABO), as a new intravascular interventional therapy, has taken more and more attention in obstetrics. Thus, the aim of this study is to evaluate the safety and efficacy of abdominal aortic balloon occlusion. Methods Retrospective analysis of pregnant women with placenta increta or percreta delivered between January 2013 and April 2019 in the Sichuan Provincial People’s Hospital. The experimental group (AABO group) included 168 patients who underwent abdominal aortic balloon occlusion before cesarean section. The control group (NO-AABO group) was composed of 106 patients who underwent surgery without any preoperative intravascular interventional therapy. The parameters containing estimated blood loss, red cell suspension (RCS) transfusion volume, hysterectomy, surgery time, postoperative hospital days, neonatal status and complications were compared between the two groups. Results The patients with preoperative abdominal aortic balloon occlusion had significant reduction in blood loss volume, red cell suspension transfusion volume and plasma transfusion volume compared to patients without balloon. Similarly, the surgery time and hysterectomy were obviously reduced in AABO group. However, there were no differences in the Apgar scores and neonatal complications between the two groups, indicating that the abdominal aortic balloon has little adverse effect on the newborns. Conclusion AABO is a safe and effective technology for pregnant women with placenta increta or percreta to reduce blood loss volume and blood transfusion volume.